NEW YORK (GenomeWeb) – Molecular diagnostics developer Exact Sciences announced today that it plans to offer 8.5 million shares of common stock for sale at $15.50 a share.

The company — which earlier this week said it would offer 7 million shares but raised the amount of the offering because of market demand — said it will use the proceeds for general corporate and working capital purposes, to fund the development of new products, and to fund the commercialization of its Cologuard colorectal cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.